Navigation Links
ABR-Affinity BioReagents Finalizes Agreement for Distribution of Osenses Antibodies in the U.S., Canada and Europe
Date:3/3/2008

DENVER and GOLDEN, Colo., March 3 /PRNewswire/ -- ABR-Affinity BioReagents, a leading global antibody manufacturer, announced today the finalization of a reverse distribution agreement with Osenses Pty. Ltd., an Australian-based manufacturer of life science reagents. Further expanding its already extensive portfolio of 100% quality guaranteed research antibodies, ABR is now an authorized distributor of Osenses products in the U.S., Europe and Canada.

Osenses offers primary antibodies for experimental use in the areas of chemosensory receptors (olfactory, vomeronasal and trace amine-associated), and visual, auditory and transient receptors. According to Ken Wilczek, President of ABR-Affinity BioReagents, "Partnering with Osenses enhances our ability to offer experimental research tools to scientists who are active in the increasingly important realm of sensory neuronal research." Encompassing antibodies for olfactory receptors, market proteins and stem cells, the Osenses product line will round out ABR's existing antibody portfolio, which now comprises more than 36,000 quality-guaranteed antibodies and research reagents.

"This type of reverse distribution arrangement allows us to utilize our already strong sales channels to really help get these unique products into the hands of research scientists who are performing cutting edge research on a daily basis," noted Ken Wilczek, President of ABR. Beginning in 2005, ABR-Affinity BioReagents implemented a strategy to investigate and partner with select worldwide antibody suppliers who produce quality products for distribution through ABR into the U.S. Other reverse distribution partners currently include: Abnova, Ab Frontier, Antibody Shop, Good Biotech and Genesis.

About ABR-Affinity BioReagents

Founded in 1989 with world headquarters in Golden, Colorado, ABR-Affinity BioReagents is a world leader in the manufacture and distribution of monoclonal and polyclonal antibodies, kits, recombinant proteins, siRNA, and custom antibody production services, known as Antibody on Demand.

With more than 36,000 antibodies focused in 43 research areas, ABR offers a unique value proposition in the life science industry-research antibodies that are 100% quality guaranteed or your money back-with no questions asked.

Utilizing a distribution network encompassing over 60 nations, ABR products are readily available in every research market on the globe. Products are available directly from ABR in the United States, as well as through an exclusive distribution partnership with Fisher Scientific, a division of Thermo Fisher Scientific.

For additional information about ABR-Affinity BioReagents, contact Leslie Martin with ABR media relations at 1-800-527-4535.


'/>"/>
SOURCE ABR-Affinity BioReagents
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ABR-Affinity BioReagents to Exhibit at ASCB in Washington D.C., December 1 - 5, 2007
2. ABR-Affinity BioReagents Announces Agreements for U.S. Distribution of Research Antibodies
3. BioWa Announces Expansion of License Agreement with Genentech for BioWas POTELLIGENT(R) Technology
4. Wyeth Pharmaceuticals Ends Collaboration Agreements with Solvay Pharmaceuticals for Bifeprunox and Other Compounds
5. Touch Bionics signs U.S. distribution agreement with SPS
6. Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
7. Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement
8. ThermoGenesis Subsidiary Vantus Announces Stem Cell Agreement With UC Davis Center For Equine Health
9. Sangamo BioSciences Announces Expansion of Research and License Agreement With Genentech for ZFP Technology for Protein Pharmaceutical Production
10. Sigma-Aldrich and MorphoSys Enter Into a Collaboration and Licensing Agreement for Recombinant Research Antibodies
11. Purchase Agreement for Antibody Manufacturing Facility Receives Antitrust Clearance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... ... May 23, 2017 , ... Federal funding for basic and applied scientific ... life-saving medical and other vital technologies — deserves continued support, say leaders of ... scientific community today in responding to the President’s budget request for Fiscal Year 2018. ...
(Date:5/23/2017)... ... , ... A recent survey conducted by the Weed Science Society of America ... 12 categories of broadleaf crops, fruits and vegetables, while common lambsquarters ranks as the ... participated in the 2016 survey, the second conducted by WSSA. A 2015 baseline ...
(Date:5/23/2017)... BELLINGHAM, Washington, USA (PRWEB) , ... May 22, ... ... SPIE Optics and Photonics 2017 in San Diego, California, this August ... virtual reality, solar fuels, and autonomous vehicles. , SPIE Optics and Photonics, the ...
(Date:5/23/2017)... ... 2017 , ... Bacterial biofilms, surface adherent communities of bacteria that are encased ... food poisoning and catheter infections to gum disease and the rejection of medical implants. ... dollars per year, there is currently a paucity of means for preventing their formation ...
Breaking Biology Technology:
(Date:4/19/2017)... New York , April 19, 2017 ... competitive, as its vendor landscape is marked by the ... the market is however held by five major players ... Safran. Together these companies accounted for nearly 61% of ... of the leading companies in the global military biometrics ...
(Date:4/17/2017)... 2017 NXT-ID, Inc. (NASDAQ: NXTD ) ... of its 2016 Annual Report on Form 10-K on Thursday April ... ... in the Investor Relations section of the Company,s website at ... at http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/13/2017)... According to a new market research report "Consumer ... Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - ... to grow from USD 14.30 Billion in 2017 to USD 31.75 Billion ... ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):